OSE Immunotherapeutics Seeks Partner For Lead Drug

Dec 22 2017

• By Lucie Ellis-Taitt

OSE Immunotherapeutics targets lead drug at NSCLC patients that don't benefit from PD-1s

More from Start-Ups & SMEs

More from Business